VYNE Therapeutics Inc. (VYNE) Institutional Ownership

Ownership Summary

VYNE Therapeutics Inc. (NASDAQ:VYNE) has 44 institutional investors that have filed 13F reports for the period ending December 2025.

• These investors collectively held 19.8% of VYNE Therapeutics's outstanding shares in December 2025, up from 9.3% in September 2025.
• Their total shares held in VYNE increased 182.88% from the prior quarter, while the number of investors in VYNE Therapeutics increased 22.22% year over year.
• Of these 44 holders, 22 added to their stakes in VYNE Therapeutics, 9 trimmed positions, and 13 made no changes.
• Combined, these investors held 8.49Mn shares in VYNE for December 2025, up by 5.49Mn shares quarter on quarter, and up 855.98K shares year over year.
• As of December 31, 2025, Nantahala Capital Management, LLC held the largest stake in VYNE Therapeutics with 2.0Mn shares, accounting for 4.67% of total shares outstanding.
• The most significant purchases of VYNE for the quarter ending December 2025 came from Lynx1 Capital Management LP (1.63Mn), Nantahala Capital Management, LLC (1.0Mn), BRAIDWELL LP (916.08K), ADAR1 Capital Management, LLC (556.32K), CITADEL ADVISORS LLC (483.92K).
• The largest sales of VYNE for the quarter ending December 2025 came from ACADIAN ASSET MANAGEMENT LLC (256.7K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (42.56K), Anson Funds Management LP (31.28K), Shay Capital LLC (14.11K), Royal Bank Of Canada (2.43K).
• Per Business Quant, the top 10 investors in VYNE for the quarter ending December 2025 include Nantahala Capital Management, LLC (2.0Mn), Lynx1 Capital Management LP (1.63Mn), Shay Capital LLC (1.61Mn), Anson Funds Management LP (1.24Mn), ADAR1 Capital Management, LLC (1.06Mn), T3 Companies, LLC (945.0K), BRAIDWELL LP (916.08K), CITADEL ADVISORS LLC (514.44K), KVP Capital Advisors, LP (500.55K), TWO SIGMA INVESTMENTS, LP (426.41K).